Population characteristics for patients with renal impairment treated with novel agents.

The HDT patients are those that at some point have received high-dose treatment, irrespective of treatment line and the non-HDT those that have not. Patients classified has having received novel drugs implies that they have received this treatment in one or more treatment lines.HDT, high-dose treated; non-HDT, non-high-dose treated; MM, multiple myeloma; IgG, immunoglobulin G; IgA, immunoglobulin A; BJ, Bence Jones; Hb, hemoglobin; Ca, calcium; β2μ, beta-2-mikroglobulin.